Institutional Investors Positive on Nektar Therapeutics (NASDAQ:NKTR)

January 19, 2018 - By Richard Conner

 Institutional Investors  Positive on Nektar Therapeutics (NASDAQ:NKTR)

Sentiment for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) institutional sentiment decreased to 1.4 in 2017 Q3. Its down -0.49, from 1.89 in 2017Q2. The ratio dived, as 94 active investment managers increased or started new equity positions, while 67 sold and trimmed equity positions in Nektar Therapeutics. The active investment managers in our partner’s database now possess: 148.76 million shares, up from 147.16 million shares in 2017Q2. Also, the number of active investment managers holding Nektar Therapeutics in their top 10 equity positions increased from 2 to 5 for an increase of 3. Sold All: 15 Reduced: 52 Increased: 68 New Position: 26.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $11.05 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

The stock increased 1.10% or $0.76 during the last trading session, reaching $70.16. About 1.55 million shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since January 19, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on March, 7. They expect $-0.35 earnings per share, down 25.00 % or $0.07 from last year’s $-0.28 per share. After $0.37 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -194.59 % negative EPS growth.

Camber Capital Management Llc holds 7.91% of its portfolio in Nektar Therapeutics for 5.20 million shares. First Light Asset Management Llc owns 503,193 shares or 3.82% of their US portfolio. Moreover, Bridger Management Llc has 3.27% invested in the company for 2.27 million shares. The Florida-based Harvey Capital Management Inc has invested 2.78% in the stock. Rhenman & Partners Asset Management Ab, a Sweden-based fund reported 866,194 shares.#img1#

Since January 1, 0001, it had 0 buys, and 18 sales for $19.24 million activity.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Ratings analysis reveals 100% of Nektar Therapeutics’s analysts are positive. Out of 9 Wall Street analysts rating Nektar Therapeutics, 9 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $16 while the high is $80.0. The stock’s average target of $38.29 is -45.42% below today’s ($70.16) share price. NKTR was included in 21 notes of analysts from August 6, 2015. J.P. Morgan maintained the shares of NKTR in report on Tuesday, July 18 with “Buy” rating. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Aegis Capital on Tuesday, November 8. The company was downgraded on Wednesday, August 26 by TheStreet. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Roth Capital on Monday, September 21. As per Thursday, July 20, the company rating was maintained by Roth Capital. Jefferies maintained it with “Buy” rating and $23.0 target in Wednesday, August 16 report. Roth Capital maintained Nektar Therapeutics (NASDAQ:NKTR) on Wednesday, August 9 with “Buy” rating. Roth Capital maintained the stock with “Buy” rating in Wednesday, August 30 report. The rating was maintained by Roth Capital with “Buy” on Monday, November 13. As per Thursday, November 9, the company rating was initiated by Canaccord Genuity.

More important recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: which released: “Why Nektar Therapeutics, Franklin Covey, and BP Prudhoe Bay Royalty Trust …” on January 09, 2018, also published article titled: “Nektar Therapeutics’ President and CEO, Howard Robin, To Present at the 36th …”, published: “Nektar Therapeutics (NKTR) Climbs 20%” on January 09, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) was released by: and their article: “The case for Cara Therapeutics” with publication date: January 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: